January 2018 Pharmacy & Therapeutics Committee Decisions

Size: px
Start display at page:

Download "January 2018 Pharmacy & Therapeutics Committee Decisions"

Transcription

1 UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for the Medicare formularies are tentative until UCare receives final CMS approval. Key: Medicare: UCare for Seniors, EssentiaCare, Minnesota Senior Health Options & Connect + Medicare and Employer Group Medicaid: PMAP, MnCare, MSC+ & Connect Exchange: UCare Choices & Fairview Choices NF = Non-formulary PA = Prior Authorization QL = Quantity Limit ST = Step Therapy Drug Indication Formulary Action Effective Date Baxdela indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates, including Methicillin-Resistant Staphylococcus Aureus (MRSA). Benznidazole indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi. Fiasp Symproic to improve glycemic control in adults with diabetes. indicated for the treatment of opioidinduced constipation (OIC) in adult patients with chronic non-cancer pain. Formularies with Prior Authorization Endari To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. Mylotarg Treatment of newly-diagnosed CD33- positive acute myeloid leukemia (AML) in adults and for the treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patient s 2 years of age. Medicare January 2018 P&T Decisions Page 1

2 Nerlynx Kymriah The extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2) overexpressed/amplified (i.e., HER2 positive [HER2+]) breast cancer, to follow adjuvant Herceptin (trastuzumab intravenous infusion) based therapy. Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or two relapses. w/pa w/pa w/pa formularies with Prior Authorization. Yescarta Aliqopa Besponsa Calquence Shingrix Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, highgrade B-cell lymphoma, and DLBCL arising from follicular lymphoma. or the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. This agent was granted accelerated approval and priority review as well as an Orphan Drug designation. indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The agent received priority review from the FDA, and was designated as a breakthrough therapy. It also was granted an orphan drug designation. Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. Shingrix is indicated for the prevention of herpes zoster (shingles) in adults 50 years of age and older. Shingrix is not indicated for the prevention of primary varicella infection (chickenpox). w/pa w/pa w/pa formularies with Prior Authorization. Bevyxxa indicated for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic January 2018 P&T Decisions Page 2

3 complications due to moderate or severe restricted mobility and other risk factors for VTE. New Generics Review All formulary changes noted are effective. Formulary coverage for each plan listed: Current Formulary Status/Proposed Formulary Status. F=Formulary NF=Non-Formulary DAPSONE 5% GEL First Generics for: ACZONE NOREPINEPHRINE 8 MG/250 ML-D5W First Generics for: NOREPINEPHRINE BITARTRATE-D5W UFS: F/F MSHO: F/F SPP: NF/NF CASPOFUNGIN ACETATE 70 MG VIAL First Generics for: CANCIDAS UFS: F/F MSHO: F/F SPP: NF/NF CARVEDILOL ER 10 MG CAPSULE CARVEDILOL ER 20 MG CAPSULE CARVEDILOL ER 40 MG CAPSULE CARVEDILOL ER 80 MG CAPSULE Generics for: COREG CR TESTOSTERONE 50 MG/5 GRAM GEL First Generics for: TESTIM UFS: NF/NF MSHO: NF/NF SPP: F/F IODOQUINOL-HYDROCORT-ALOE GEL First Generics for: ALCORTIN A UFS: F/F MSHO: F/F SPP: NF/NF OSELTAMIVIR 6 MG/ML SUSPENSION First Generics for: TAMIFLU FLUOXETINE HCL 60 MG TABLET First Generics for: FLUOXETINE HCL UFS: NF/F MSHO: NF/F SPP: NF/NF January 2018 P&T Decisions Page 3

4 TIMOLOL 0.5% EYE DROPS First Generics for: ISTALOL UFS: NF/F MSHO: NF/F SPP: NF/NF TIGECYCLINE 50 MG VIAL First Generics for: TYGACIL UFS: F/F MSHO: F/F SPP: NF/NF SILDENAFIL 100 MG TABLET SILDENAFIL 25 MG TABLET SILDENAFIL 50 MG TABLET First Generics for: VIAGRA New Indications Review All formulary changes noted are effective. Formulary coverage for each plan listed: Current Formulary Status/Proposed Formulary Status. F=Formulary, NF=Non-Formulary Vimpat (lacosamide tablets) Zelboraf (vemurafenib tablet) Alecensa (alectinib capsules) Auryxia (ferric citrate tablets) Adcetris (brentuximab vedotin injection) Sprycel (dasatinib tablets) Faslodex (fulvestrant injection) Tekturna (aliskiren tablets) UFS: F/F MSHO: F/F SPP: NF/NF Gazyva (obinutuzumab injection) January 2018 P&T Decisions Page 4

5 Sutent (sunitinib malate capsules) Tivicay (dolutegravir tablets) Triumeq (abacavir, dolutegravir, and lamivudine tablets) Isentress (raltegravir tablets) Taltz (ixekizumab injection) Repatha (evolocumab injection) Avastin (bevacizumab solution for intravenous [IV] infusion) UFS: F/F MSHO: F/F SPP: NF/NF Levo-T (levothyroxine sodium tablets) Nucala (mepolizumab injection, for subcutaneous [SC] use) Xeljanz (tofacitinib tablets) UFS: NF/NF MSHO: NF/NF SPP: F/F Xeljanz XR (tofacitinib extended-release tablets) Bosulif (bosutinib tablets) Cabometyx (cabozantinib tablets) Opdivo (nivolumab injection) Perjeta (pertuzumab injection, for intravenous [IV] use) January 2018 P&T Decisions Page 5

6 UFS: F/F MSHO: F/F SPP: NF/NF Procysbi (cysteamine bitartrate delayed-release capsules) Miscellaneous Previously Reviewed Items All formulary changes noted are effective. Formulary coverage for each plan listed: Current Formulary Status/Proposed Formulary Status. F=Formulary, NF=Non-Formulary FLOLIPID 20 MG/5 ML & 40 MG/5 ML (SIMVASTATIN) ORAL SUSP DUZALLO MG & MG (LESINURAD/ALLOPURINOL) TABLET CAROSPIR 25 MG/5 ML (SPIRONOLACTONE) SUSPENSION ZILRETTA 32 MG (TRIAMCINOLONE ACETONIDE) VIAL January 2018 P&T Decisions Page 6

June 2018 Pharmacy & Therapeutics Committee Decisions

June 2018 Pharmacy & Therapeutics Committee Decisions UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed

More information

September 2018 Pharmacy & Therapeutics Committee Decisions

September 2018 Pharmacy & Therapeutics Committee Decisions UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to UCare (approved drug list). These changes are reviewed based

More information

March 2017 Pharmacy & Therapeutics Committee Decisions

March 2017 Pharmacy & Therapeutics Committee Decisions UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed

More information

March 2018 Pharmacy & Therapeutics Committee Decisions

March 2018 Pharmacy & Therapeutics Committee Decisions UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed

More information

HealthLine. Focus on Heart Failure Part 2: Treatment Considerations

HealthLine. Focus on Heart Failure Part 2: Treatment Considerations December 2017 THE OMNICARE HealthLine Focus on Heart Failure Part 2: Treatment Considerations Several studies have demonstrated that a lack of using guideline-directed therapy is associated with increased

More information

Cancer Therapy Update in 2017

Cancer Therapy Update in 2017 Cancer Therapy Update in 2017 Editor: Le Wang, M.D., Ph.D Medical Oncology and Hematology (Board-Certified) Ibrutinib (Imbruvica) Pharmacyclics 1 /19/2017 Lymphoma Marginal Zone Lymphoma (MZL), Relapsed/Refractory

More information

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates July 2018 TRADE NAME (generic name) or generic name ADVAIR DISKUS (fluticasone-salmeterol aer powder ba 100-50 mcg/dose) Brand Addition ADVAIR

More information

FDA Approval LIST. WellINFORMED. Generic Name(s) Brand Name (manufacturer) Therapeutic Use. Brief Description. Potential Impact.

FDA Approval LIST. WellINFORMED. Generic Name(s) Brand Name (manufacturer) Therapeutic Use. Brief Description. Potential Impact. FDA Approval LIST Formulary management is one way to bring down drug costs, and deciding which medications to include on a formulary is part of this process. New drug releases are generally associated

More information

NOTIFICATION OF FORMULARY CHANGES

NOTIFICATION OF FORMULARY CHANGES NOTIFICATION OF CHANGES The following summary describes changes to the 2018 Presbyterian Senior Care (HMO)/(HMO-POS), Presbyterian MediCare PPO and formularies. The formulary may change at any time. You

More information

Well Informed. WellManaged - Diabetes INTRODUCING: WellDyneRx plan participants are eligible to receive a free One Touch System glucose meter

Well Informed. WellManaged - Diabetes INTRODUCING: WellDyneRx plan participants are eligible to receive a free One Touch System glucose meter Q4 2 0 1 7 Well Informed With 2017 winding down, we re taking stock of how we performed throughout the year and setting goals for 2018. Towards that end, we recently distributed our annual Client Satisfaction

More information

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary April 1, 2018 Updates. Formulary Alternatives

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary April 1, 2018 Updates. Formulary Alternatives PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select April 1, 2018 Updates Drug Name adapalene-benzoyl-peroxide Gel 0.1-2.5% (Brand = Epiduo ) prasugrel hcl (Brand = Effient ) vigabatrin pak 500 mg (Brand

More information

2018 CareOregon Advantage Part D Formulary Changes

2018 CareOregon Advantage Part D Formulary Changes 2018 CareOregon Advantage Part D Formulary Changes Abbreviations: AGE = Age Restriction; PA = Prior Authorization Required; QL = Quantity Limit; ST = Step Therapy Required; LD = Limited Distribution; BvD

More information

2018 Formulary Update

2018 Formulary Update MEDICARE ADVANTAGE BlueShield of Northeastern New York 2018 Formulary Update BlueShield of Northeastern New York has updated its formulary (drug list) since its original publication in January 2018. This

More information

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary April 1, 2018 Updates. Formulary Alternatives

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary April 1, 2018 Updates. Formulary Alternatives PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select April 1, 2018 Updates Drug Name adapalene-benzoyl-peroxide Gel 0.1-2.5% (Brand = Epiduo ) prasugrel hcl (Brand = Effient ) vigabatrin pak 500 mg (Brand

More information

P&T/Formulary Committee Actions (1Q18)

P&T/Formulary Committee Actions (1Q18) P&T/Formulary Committee s (1Q18) 1Q2018 Marketplace Standard (HIEx) Additions and/or Revisions effective: April 1, 2018 Deletions effective: April 1, 2018 for NEW member prescriptions; July 1, 2018 for

More information

Memorial Hermann Advantage HMO February 2019 Formulary Addendum

Memorial Hermann Advantage HMO February 2019 Formulary Addendum Memorial Hermann Advantage HMO February 2019 Formulary Addendum Changes may have occurred since the printing of your current Memorial Hermann Advantage HMO Formulary. Medications that may have been added

More information

ELEVATE. Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard)

ELEVATE. Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard) ELEVATE Formulary Updates to Elevate Plans (Bronze HDHP/Standard, Silver Select/Standard & Gold Select/Standard) P&T/Formulary Committee Actions 4Q 2017 (Effective January 1, 2018) Marketplace Standard

More information

NEW FDA DRUG APPROVALS

NEW FDA DRUG APPROVALS NEW FDA DRUG APPROVALS Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies Las Vegas, NV March 15, 2018 Disclosures We have nothing

More information

Presbyterian Health Plan, Inc. Presbyterian Insurance Company, Inc. NOTIFICATION OF FORMULARY CHANGES

Presbyterian Health Plan, Inc. Presbyterian Insurance Company, Inc. NOTIFICATION OF FORMULARY CHANGES NOTIFICATION OF FORMULARY CHANGES The following summary describes changes to the Presbyterian Commercial Large Group Plans (Non-Metal Plans) Formularies effective 2018. For the most recent list of drugs,

More information

Medicare Part D 2016 Formulary Changes Service To Senior and OC Preferred

Medicare Part D 2016 Formulary Changes Service To Senior and OC Preferred Medicare Part D 2016 Formulary s Service To Senior and OC Preferred Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 09.26.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder

More information

You ll find the most up-to-date comprehensive version of our formulary on our website, Click on Drug Finder.

You ll find the most up-to-date comprehensive version of our formulary on our website,   Click on Drug Finder. 3/1/2018 Medicare Part D Formulary Change In an effort to cover the most needed, cost-effective prescriptions, the AlohaCare Advantage Plus (HMO SNP) Formulary is updated monthly. The following are drugs

More information

Superior Select Health Plans: Tribute-1 Tier May 2018 Formulary Addendum

Superior Select Health Plans: Tribute-1 Tier May 2018 Formulary Addendum Superior Select Health Plans: Tribute-1 Tier May 2018 Formulary Addendum Below is a list formulary changes for the benefit year 2018. This is not a complete list of drugs covered by the Part D plan. The

More information

Presbyterian Health Plan, Inc. Presbyterian Insurance Company, Inc. NOTIFICATION OF FORMULARY CHANGES

Presbyterian Health Plan, Inc. Presbyterian Insurance Company, Inc. NOTIFICATION OF FORMULARY CHANGES NOTIFICATION OF FORMULARY CHANGES The following summary describes changes to the 2017 Presbyterian Individual and Family Metal Plan/Employer Group Metal Plan Formularies effective 2018. For the most recent

More information

Contents Please refer to Medical Policy I-40 Pertuzumab (Perjeta) for additional information.

Contents Please refer to Medical Policy I-40 Pertuzumab (Perjeta) for additional information. May 2018 In This Issue Coverage Guidelines Revised for Azacitidine (Vidaza)... 3 Coverage Guidelines Revised for Fulvestrant (Faslodex)... 4 Place of Service Revised for Total Hip and Total Knee Arthroplasty...

More information

Drug Formulary Update, April 2013

Drug Formulary Update, April 2013 Drug Formulary Update, April 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota

More information

2017 Formulary Addendum Notice of Change

2017 Formulary Addendum Notice of Change 2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) WellCare Health Plans WellCare Access (HMO SNP), WellCare Liberty (HMO SNP), WellCare Reserve (HMO), WellCare Rx (HMO), WellCare Select

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at

More information

Changes to the 2018 BlueCross Secure SM (HMO) & BlueCross Total SM (PPO) Formularies

Changes to the 2018 BlueCross Secure SM (HMO) & BlueCross Total SM (PPO) Formularies Changes to the 2018 BlueCross Secure SM (HMO) & BlueCross Total SM (PPO) Formularies BlueCross BlueShield of South Carolina may add or remove drugs from the formulary during the year. If we remove drugs

More information

2017 Formulary Addendum Notice of Change

2017 Formulary Addendum Notice of Change 2017 Formulary Addendum Notice of Change (Prescription Drug Plans) WellCare Prescription Insurance, Inc. WellCare Classic (PDP) WellCare Extra (PDP) This is a listing of the changes that have occurred

More information

2018 Step Therapy (ST) Criteria

2018 Step Therapy (ST) Criteria 2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a

More information

2018 Medicare Part D Formulary Change

2018 Medicare Part D Formulary Change 2018 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy

More information

2017 Formulary Addendum Notice of Change

2017 Formulary Addendum Notice of Change 017 Formulary Addendum Notice of Change (Medicare Advantage Plans) WellCare Health Plans WellCare Choice (HMO), WellCare Essential (HMO-POS), WellCare Value (HMO) This is a listing of the changes that

More information

2017 Formulary Addendum Notice of Change (Prescription Drug Plans)

2017 Formulary Addendum Notice of Change (Prescription Drug Plans) 2017 Formulary Addendum Notice of Change (Prescription Drug Plans) WellCare Prescription Insurance, Inc. WellCare Classic (PDP) WellCare Extra (PDP) This is a listing of the changes that have occurred

More information

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) 2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) Easy Choice Health Plan Easy Choice Freedom Plan (HMO SNP) H5087-001 This is a listing of the changes that have occurred in our formulary.

More information

Kymriah. Kymriah (tisagenlecleucel) Description

Kymriah. Kymriah (tisagenlecleucel) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah

More information

NEW FDA DRUG APPROVALS

NEW FDA DRUG APPROVALS NEW FDA DRUG APPROVALS Jennifer Peterson MSN, RN, OCN, BMTCN Jennifer Shamai MS, RN, AOCNS, BMTCN How the Experts Treat Hematologic Malignancies Las Vegas, NV March 15, 2018 Disclosures We have nothing

More information

2016 Step Therapy (ST) Criteria

2016 Step Therapy (ST) Criteria 2016 Step Therapy (ST) Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a drug that

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia

More information

Bosulif. Bosulif (bosutinib) Description

Bosulif. Bosulif (bosutinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review

More information

Health Partners Medicare Special 2018 Formulary Changes

Health Partners Medicare Special 2018 Formulary Changes Health Partners Medicare Special 2018 Changes Changes occur, for example, because new drugs come on the market, a drug is moved to a different cost-sharing level (tier), or a generic version becomes available.

More information

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Investor Update Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal

More information

Yescarta. Yescarta (axicabtagene ciloleucel) Description

Yescarta. Yescarta (axicabtagene ciloleucel) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta

More information

Drug Class Review Monograph GPI Class 12 Antivirals

Drug Class Review Monograph GPI Class 12 Antivirals Drug Class Review Monograph GPI Class 12 Antivirals Review Time Frame: 02/2016 04/2017 Previous Class Review: 05/2016 Background: Antiviral agents are used to treat infections caused by viruses, including,

More information

2015 Step Therapy (ST) Criteria

2015 Step Therapy (ST) Criteria 2015 Step Therapy (ST) Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a drug that

More information

Drug Name Description of Change Formulary Coverage Formulary Alternative(s)

Drug Name Description of Change Formulary Coverage Formulary Alternative(s) NOTIFICATION OF FORMULARY CHANGES The following summary describes changes to the Presbyterian Centennial Care Formulary effective 2018. For the most recent list of drugs, information on asking for a prior

More information

2019 STEP THERAPY CRITERIA UCare Connect + Medicare (SNBC) (HMO SNP) UCare s Minnesota Senior Health Options (MSHO) (HMO SNP)

2019 STEP THERAPY CRITERIA UCare Connect + Medicare (SNBC) (HMO SNP) UCare s Minnesota Senior Health Options (MSHO) (HMO SNP) 2019 STEP THERAPY CRITERIA UCare Connect + Medicare (SNBC) (HMO SNP) UCare s Minnesota Senior Health Options (MSHO) (HMO SNP) In some cases, UCare s MSHO and UCare Connect + Medicare require you to first

More information

2018 Medicare Part D Formulary Change

2018 Medicare Part D Formulary Change 2018 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy

More information

2018 Formulary Update

2018 Formulary Update MEDICARE ADVANTAGE BlueShield of Northeastern New York 2018 Formulary Update BlueShield of Northeastern New York has updated its formulary (drug list) since its original publication in January 2018. This

More information

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Media Release Basel, 8 May 2018 Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting New and updated pivotal combination

More information

New Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications

New Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications Q4 2017 Advair Diskus salmeterol Asthma, COPD inhaler Advair HFA salmeterol Asthma inhaler Airduo Respiclick salmeterol Asthma inhaler Alecensa alectinib Non-Small Cell Lung Cancer Genentech announced

More information

2017 Formulary Changes Year to Date

2017 Formulary Changes Year to Date 2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or

More information

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved. Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.

More information

Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications

Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications Stratified medicine in practice: Review of predictive biomarkers in European Medicines Agency (EMA) indications Kinga Malottki, Mousumi Biswas, Jon Deeks, Richard Riley, Charles Craddock, Lucinda Billingham

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Afinitor, Afinitor Disperz) Reference Number: CP.PHAR.63 Effective Date: 06.01.11 Last Review Date: 08.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder

More information

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) 207 Formulary Addendum Notice of Change (Medicare Advantage Plans) Easy Choice Health Plan Easy Choice Plus Plan (HMO) H5087-002, H5087-07 This is a listing of the changes that have occurred in our formulary.

More information

Drugs Not Approved By the Scottish Medicines Consortium

Drugs Not Approved By the Scottish Medicines Consortium January 2017 Vol. 14 No. 1 Outlined below in this newsletter are the recommendations for new drugs which have been through the ly agreed process (see appendix I). Please remember that the ADTC advises

More information

ORAL ONCOLOGY CRITERIA

ORAL ONCOLOGY CRITERIA ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) 2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) Easy Choice Health Plan Easy Choice Best Plan (HMO) H5087-005 This is a listing of the changes that have occurred in our formulary. Please

More information

2018 STEP THERAPY CRITERIA UCare Connect + Medicare (SNBC) (HMO SNP) UCare s Minnesota Senior Health Options (MSHO) (HMO SNP)

2018 STEP THERAPY CRITERIA UCare Connect + Medicare (SNBC) (HMO SNP) UCare s Minnesota Senior Health Options (MSHO) (HMO SNP) 2018 STEP THERAPY CRITERIA UCare Connect + Medicare (SNBC) (HMO SNP) UCare s Minnesota Senior Health Options (MSHO) (HMO SNP) In some cases, UCare s MSHO and UCare Connect + Medicare require you to first

More information

intolerance to, contraindication to, or therapeutic failure on a minimum 3 month trial of Inflectra*

intolerance to, contraindication to, or therapeutic failure on a minimum 3 month trial of Inflectra* What s New Medical Pharmaceutical Policy March 2018 Updates MBP 5.0 Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)- Updated policy Remicade (infliximab), Inflectra (infliximab-dyyb)

More information

RENAL CELL CARCINOMA CLINICAL MANAGEMENT

RENAL CELL CARCINOMA CLINICAL MANAGEMENT page 1 / 5 page 2 / 5 renal cell carcinoma clinical pdf Haematological Malignancies. Waldenstrom's macroglobulinaemia Chronic myeloid leukaemia Newly diagnosed and relapsed mantle cell lymphoma Multiple

More information

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice MEDICAID PROVIDER BULLETIN March 2019 Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at the fourth quarter pharmacy and therapeutics

More information

Medicare Part D 2016 Formulary Changes Desert Preferred Choice

Medicare Part D 2016 Formulary Changes Desert Preferred Choice Medicare Part D 2016 Formulary s Desert Preferred Choice Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization,

More information

Iclusig. Iclusig (ponatinib) Description

Iclusig. Iclusig (ponatinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.30 Subject: Iclusig Page: 1of 6 Last Review Date: June 22, 2018 Iclusig Description Iclusig (ponatinib)

More information

During non-business hours, your call will be answered by our automated phone system. A representative will return your call the next business day.

During non-business hours, your call will be answered by our automated phone system. A representative will return your call the next business day. MEICARE AVANTAGE BlueCross BlueShield of Western New York 2018 Formulary Update BlueCross BlueShield of Western New York has updated its formulary (drug list) since its original publication in January

More information

2018 Formulary Notice of Change Prescription Drug Plans

2018 Formulary Notice of Change Prescription Drug Plans 2018 Formulary Notice of Change Prescription Drug Plans WellCare Prescription Insurance, Inc. Plans in all states: WellCare Classic (PDP) WellCare may add or remove drugs from our formulary during the

More information

Partners Notice of Change March 2017

Partners Notice of Change March 2017 New Added Products: Effective 3/1/2017 Drug Reason Tier Restrictions abacavir 600 mg-lamivudine 300 QL ADRENACLICK 0.15 MG/0.15 ML INJECTION,AUTO- INJECTOR ADRENACLICK 0.3 MG/0.3 ML INJECTION, AUTO- INJECTOR

More information

ORAL ONCOLOGY CRITERIA

ORAL ONCOLOGY CRITERIA ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

RITUXAN (rituximab and hyaluronidase human)

RITUXAN (rituximab and hyaluronidase human) Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria

More information

INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]

INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY] Commercial Medical Oncology Program Review Code List 3rd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of

More information

New Developments in Cancer Treatment. Dulcinea Quintana, MD

New Developments in Cancer Treatment. Dulcinea Quintana, MD New Developments in Cancer Treatment Dulcinea Quintana, MD Mortality Rates Goals of treatment 1 Cure Goal of treatment 2 Prolong life Goals of treatment 3 Improve Quality of Life Goals of treatment 4

More information

Drug Formulary Update, January 2013

Drug Formulary Update, January 2013 Drug Formulary Update, January 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota

More information

YESCARTA (axicabtagene ciloleucel)

YESCARTA (axicabtagene ciloleucel) YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices

More information

Clinical Policy: Idelalisib (Zydelig) Reference Number: ERX.SPA.269 Effective Date:

Clinical Policy: Idelalisib (Zydelig) Reference Number: ERX.SPA.269 Effective Date: Clinical Policy: (Zydelig) Reference Number: ERX.SPA.269 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Added, Removed or Changed. Added, Removed or Changed

Added, Removed or Changed. Added, Removed or Changed One mission: you s March 8, 2018 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your

More information

Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities

Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with

More information

Cash Wise Pharmacy $4 GENERIC MEDICATION FORMULARY. Cash Wise Pharmacy s $4 generic medication formulary is sorted by medical condition.

Cash Wise Pharmacy $4 GENERIC MEDICATION FORMULARY. Cash Wise Pharmacy s $4 generic medication formulary is sorted by medical condition. Cash Wise Pharmacy $4 GENERIC MEDICATION FORMULARY Cash Wise Pharmacy s $4 generic medication formulary is sorted by medical condition. 30- day 90- day 30- day 90- day quantity quantity quantity quantity

More information

CPT Service Description Effective Date

CPT Service Description Effective Date Medical Oncology Program Review Code List 2 nd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of January, April,

More information

HEALTH SHARE/PROVIDENCE (OHP)

HEALTH SHARE/PROVIDENCE (OHP) HEALTH SHARE/PROVIDENCE (OHP) STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered

More information

Cancer drug costs and payment issues in European countries.

Cancer drug costs and payment issues in European countries. Cancer drug costs and payment issues in European countries. Wim van Harten MD PhD, Riin Ots, Valesca Retel PhD, Anke Wind MSc. ECPC June 2017 Affiliations: The Netherlands Cancer Institute; University

More information

Sutent. Sutent (sunitinib) Description

Sutent. Sutent (sunitinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 6 Last Review Date: March 16, 2018 Sutent Description Sutent (sunitinib)

More information

Tasigna. Tasigna (nilotinib) Description

Tasigna. Tasigna (nilotinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)

More information

Drug Formulary Update, July 2016 Commercial and State Programs

Drug Formulary Update, July 2016 Commercial and State Programs Drug Formulary Update, July 2016 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,

More information

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440 This spreadsheet is updated monthly and enables self-audit of a medicines for All guidelines refer to adults unless indicated. No copyright is asserted on this Technology appraisal (TA) Titles are hyperlinks

More information

Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous)

Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Document Number: IC-0322 Last Review Date: 02/06/2018 Date of Origin: 7/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 05/2011,

More information

FDA Corner. Molecular and Cellular Pharmacology

FDA Corner. Molecular and Cellular Pharmacology FDA Corner FDA Approval Brings First Gene Therapy to the United States CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia This release was updated

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

Yescarta (axicabtagene ciloleucel)

Yescarta (axicabtagene ciloleucel) Last Review Date: March 30, 2018 Effective Date: April 1, 2018 Number: MG.MM.PH.42 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider

More information

Tasigna. Tasigna (nilotinib) Description

Tasigna. Tasigna (nilotinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)

More information

Science, patient benefits and productivity

Science, patient benefits and productivity Science, patient benefits and productivity Alan Hippe, CFO Roche Group London, November 2017 This presentation contains certain forward-looking statements. These forward-looking statements may be identified

More information

Prescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals)

Prescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals) This report highlights all changes (additions, deletions and removals) to the CVS Caremark Prescribing Guide Standard Control. ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Estring (estradiol)

More information

2017 Medicare Part D Formulary Change

2017 Medicare Part D Formulary Change 2017 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy

More information

Pharmacology Update. Power. Note one action you ll take after attending this session:

Pharmacology Update. Power. Note one action you ll take after attending this session: Pharmacology Update Sunday, May 20 8 9:30 am Note one action you ll take after attending this session: Teresa Knoop, MSN, RN, AOCN Vanderbilt Ingram Cancer Center Assistant Director Clinical Operations

More information

2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용

2018 KSMO Immune Oncology Forum. Immune checkpoint inhibitors in hematologic. malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018 KSMO Immune Oncology Forum Immune checkpoint inhibitors in hematologic malignancies: evidences and perspectives 서울아산병원종양내과 홍정용 2018-07-18 Contents Introduction Immune checkpoint inhibtors in lymphomas

More information

Pharmacy Medical Necessity Guidelines: Oral Cancer Medications

Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Pharmacy Medical Necessity Guidelines: Effective: February 18, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)

More information

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/

More information

Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009

Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis

More information